141 related articles for article (PubMed ID: 36041942)
1. Development and characterization of a novel conjugated methamphetamine vaccine.
Kamal Hossain M; Davidson M; Feehan J; Deraos G; Nurgali K; Matsoukas J; Apostolopoulos V
Vaccine; 2022 Sep; 40(41):5882-5891. PubMed ID: 36041942
[TBL] [Abstract][Full Text] [Related]
2. Development of Methamphetamine Conjugated Vaccine through Hapten Design: In Vitro and In Vivo Characterization.
Hossain MK; Davidson M; Feehan J; Deraos G; Nurgali K; Matsoukas J; Apostolopoulos V
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851217
[TBL] [Abstract][Full Text] [Related]
3. Vaccine development against methamphetamine drug addiction.
Hossain MK; Hassanzadeganroudsari M; Nurgali K; Apostolopoulos V
Expert Rev Vaccines; 2020 Dec; 19(12):1105-1114. PubMed ID: 33251859
[TBL] [Abstract][Full Text] [Related]
4. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse.
Peterson EC; Gunnell M; Che Y; Goforth RL; Carroll FI; Henry R; Liu H; Owens SM
J Pharmacol Exp Ther; 2007 Jul; 322(1):30-9. PubMed ID: 17452421
[TBL] [Abstract][Full Text] [Related]
5. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food.
Rüedi-Bettschen D; Wood SL; Gunnell MG; West CM; Pidaparthi RR; Carroll FI; Blough BE; Owens SM
Vaccine; 2013 Sep; 31(41):4596-602. PubMed ID: 23906885
[TBL] [Abstract][Full Text] [Related]
6. Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE.
Stevens MW; Rüedi-Bettschen D; Gunnell MG; Tawney R; West CM; Owens SM
Drug Alcohol Depend; 2019 Nov; 204():107484. PubMed ID: 31521953
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines.
Duryee MJ; Bevins RA; Reichel CM; Murray JE; Dong Y; Thiele GM; Sanderson SD
Vaccine; 2009 May; 27(22):2981-8. PubMed ID: 19428909
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines.
Carroll FI; Blough BE; Pidaparthi RR; Abraham P; Gong PK; Deng L; Huang X; Gunnell M; Lay JO; Peterson EC; Owens SM
J Med Chem; 2011 Jul; 54(14):5221-8. PubMed ID: 21682289
[TBL] [Abstract][Full Text] [Related]
9. Immune to addiction: how immunotherapies can be used to combat methamphetamine addiction.
Hossain MK; Hassanzadeganroudsari M; Kypreos E; Feehan J; Apostolopoulos V
Expert Rev Vaccines; 2021 Jun; 20(6):707-715. PubMed ID: 33970739
[No Abstract] [Full Text] [Related]
10. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse.
Carroll FI; Abraham P; Gong PK; Pidaparthi RR; Blough BE; Che Y; Hampton A; Gunnell M; Lay JO; Peterson EC; Owens SM
J Med Chem; 2009 Nov; 52(22):7301-9. PubMed ID: 19877685
[TBL] [Abstract][Full Text] [Related]
11. Consequence of Hapten Stereochemistry: An Efficacious Methamphetamine Vaccine.
Olson ME; Sugane T; Zhou B; Janda KD
J Am Chem Soc; 2019 Sep; 141(36):14089-14092. PubMed ID: 31479256
[TBL] [Abstract][Full Text] [Related]
12. Optimization of a methamphetamine conjugate vaccine for antibody production in mice.
Stevens MW; Gunnell MG; Tawney R; Owens SM
Int Immunopharmacol; 2016 Jun; 35():137-141. PubMed ID: 27039212
[TBL] [Abstract][Full Text] [Related]
13. Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors.
Keller CM; Spence AL; Stevens MW; Owens SM; Guerin GF; Goeders NE
Psychopharmacology (Berl); 2020 Mar; 237(3):655-667. PubMed ID: 31758209
[TBL] [Abstract][Full Text] [Related]
14. Impact of distinct chemical structures for the development of a methamphetamine vaccine.
Moreno AY; Mayorov AV; Janda KD
J Am Chem Soc; 2011 May; 133(17):6587-95. PubMed ID: 21473576
[TBL] [Abstract][Full Text] [Related]
15. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.
Peterson EC; Gentry WB; Owens SM
Adv Pharmacol; 2014; 69():107-27. PubMed ID: 24484976
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic landscape of amphetamine and methamphetamine addiction in rodents.
Godino A; Jayanthi S; Cadet JL
Epigenetics; 2015; 10(7):574-80. PubMed ID: 26023847
[TBL] [Abstract][Full Text] [Related]
17. Methamphetamine: Mechanism of Action and Chinese Herbal Medicine Treatment for Its Addiction.
Zeng R; Pu HY; Zhang XY; Yao ML; Sun Q
Chin J Integr Med; 2023 Jul; 29(7):665-672. PubMed ID: 37074617
[TBL] [Abstract][Full Text] [Related]
18. l-Scoulerine attenuates behavioural changes induced by methamphetamine in zebrafish and mice.
Mi G; Gao Y; Yan H; Jin X; Ye E; Liu S; Gong Z; Yang H; Yang Z
Behav Brain Res; 2016 Feb; 298(Pt A):97-104. PubMed ID: 26433144
[TBL] [Abstract][Full Text] [Related]
19. Development of active and passive human vaccines to treat methamphetamine addiction.
Gentry WB; Rüedi-Bettschen D; Owens SM
Hum Vaccin; 2009 Apr; 5(4):206-13. PubMed ID: 19276653
[TBL] [Abstract][Full Text] [Related]
20. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.
Hambuchen MD; Carroll FI; Rüedi-Bettschen D; Hendrickson HP; Hennings LJ; Blough BE; Brieaddy LE; Pidaparthi RR; Owens SM
J Med Chem; 2015 Jun; 58(11):4665-77. PubMed ID: 25973614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
